Revive Therapeutics Ltd. announced that the U.S. Food & Drug Administration has granted the Company's Type C meeting request to obtain agreement on the revised protocol endpoints for the Company's Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The goal date for the FDA to provide its written responses is March 7, 2023. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 CAD | 0.00% |
|
0.00% | -66.67% |
1st Jan change | Capi. | |
---|---|---|
-66.67% | 3.06M | |
+20.38% | 127B | |
+24.52% | 117B | |
+25.44% | 27.67B | |
-18.23% | 20.33B | |
-15.17% | 16.79B | |
-14.90% | 15.63B | |
+12.65% | 14.84B | |
-47.10% | 14.65B | |
+56.07% | 14.43B |
- Stock Market
- Equities
- RVV Stock
- News Revive Therapeutics Ltd.
- Revive Therapeutics Ltd. Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of Covid-19